Fundus neovascular diseases(FNDs)are ocular diseases caused by pathological changes in retinal blood vessels, which are the leading cause of visual impairment globally. The overexpression of vascular endothelial growth factor(VEGF)plays an important role in the formation of new blood vessels, and the current first-line treatment for FNDs is anti-VEGF drugs. The eyes have a special blood-eye barrier, which makes it difficult for eye drops, oral or intravenous drugs to enter the eye and exert their effects. Intraocular injection can bypass this barrier and directly inject drugs into the eye, which is the main route of administration for the treatment of eye diseases. Compared with systemic administration, it is more conducive to enrich the drug at the target site and reduce systemic adverse reactions. Intraocular administrations include intravitreal injection(IVI), suprachoroidal space(SCS)injection, subretinal injection(SRI), drug delivery systems and other invasive intraocular treatments. Previous studies have shown that different intraocular administration methods can affect the pharmacokinetic(PK)properties of drugs. This article reviews the PK changes of anti-VEGF drugs under different intraocular administration methods.